WEBVTT 00:00:00.000 --> 00:00:02.120 Welcome back to the Deep Dive. Our mission is 00:00:02.120 --> 00:00:04.900 always the same. We take a formidable stack of 00:00:04.900 --> 00:00:06.940 sources, we strip away all the noise, and we 00:00:06.940 --> 00:00:09.960 try to extract that pure, actionable knowledge 00:00:09.960 --> 00:00:13.300 that makes you instantly well -informed. Today, 00:00:13.419 --> 00:00:16.059 we are undertaking a deep dive into an organization 00:00:16.059 --> 00:00:19.600 that, despite operating mostly behind the scenes, 00:00:20.199 --> 00:00:22.539 really sits at the absolute center of global 00:00:22.539 --> 00:00:25.379 life sciences. So if you're preparing for a meeting, 00:00:25.539 --> 00:00:27.100 if you're trying to catch up on the pharmaceutical 00:00:27.100 --> 00:00:29.920 pipeline, or if you're just curious about how 00:00:29.920 --> 00:00:32.640 new medicine actually gets made, this company 00:00:32.640 --> 00:00:35.159 is pretty much unavoidable. It really is. We 00:00:35.159 --> 00:00:37.280 are diving into Charles River Laboratories International, 00:00:37.640 --> 00:00:41.020 Inc. This company is, well, it's the infrastructure. 00:00:41.079 --> 00:00:43.179 It's the backbone, the essential plumbing of 00:00:43.179 --> 00:00:45.380 modern drug development. Most people have never 00:00:45.380 --> 00:00:48.560 heard the name, and yet Charles River? or CRL, 00:00:48.679 --> 00:00:51.399 it's woven into the very fabric of virtually 00:00:51.399 --> 00:00:54.280 every new drug, vaccine, or medical device that's 00:00:54.280 --> 00:00:56.579 created today. So to define that core identity, 00:00:56.859 --> 00:00:59.640 what are they? CRL is an American Pharmaceutical 00:00:59.640 --> 00:01:03.159 and Biotechnology, a contract research organization. 00:01:03.500 --> 00:01:07.519 A CRO. Exactly, a CRO. And while contract research 00:01:07.519 --> 00:01:10.400 organization sounds like a title on some, I don't 00:01:10.400 --> 00:01:13.079 know, dry compliance form, its function is anything 00:01:13.079 --> 00:01:16.569 but dry. So clarify for us, what specific role 00:01:16.569 --> 00:01:20.469 does a CRO like CRL actually play in this whole 00:01:20.469 --> 00:01:23.670 life sciences ecosystem? A CRO is essentially 00:01:23.670 --> 00:01:26.450 a specialty outsourcer. I mean, think about it. 00:01:26.670 --> 00:01:29.750 Pharmaceutical companies, biotech firms, they 00:01:29.750 --> 00:01:32.469 need to run thousands of highly, highly regulated 00:01:32.469 --> 00:01:34.769 tests. Right. We're talking toxicology studies, 00:01:35.049 --> 00:01:38.569 safety assessments, efficacy trials. all to prove 00:01:38.569 --> 00:01:41.489 a compound is safe and that it works before the 00:01:41.489 --> 00:01:44.349 FDA or its international equivalents will even 00:01:44.349 --> 00:01:46.250 look at it. So they're the gatekeepers for the 00:01:46.250 --> 00:01:48.849 gatekeepers. In a way, yes. CRO provides those 00:01:48.849 --> 00:01:50.870 specialized, standardized preclinical and early 00:01:50.870 --> 00:01:53.109 clinical laboratory services. They are the engine 00:01:53.109 --> 00:01:54.930 running the tests that determine if a new compound 00:01:54.930 --> 00:01:56.849 is safe and effective enough to even continue 00:01:56.849 --> 00:01:59.870 development. Wow. Without that outsourced infrastructure, 00:02:00.129 --> 00:02:02.230 the development process for new medicine would 00:02:02.230 --> 00:02:05.430 just, it would slow to a crawl. And... They do 00:02:05.430 --> 00:02:07.670 this at an industrial scale that, frankly, is 00:02:07.670 --> 00:02:09.969 a little hard to believe. This is a publicly 00:02:09.969 --> 00:02:13.009 traded company on the NYSE, ticker CRL. It's 00:02:13.009 --> 00:02:15.969 an S &P 500 component, and it operates in at 00:02:15.969 --> 00:02:19.189 least 20 countries worldwide. Just look at the 00:02:19.189 --> 00:02:24.110 raw numbers from 2024. $4 .5 billion in revenue 00:02:24.110 --> 00:02:27.949 and over 20 ,100 employees globally. That's not 00:02:27.949 --> 00:02:30.770 just a lab. That's a global industrial powerhouse. 00:02:30.949 --> 00:02:32.990 And it functions as the critical bottleneck for 00:02:32.990 --> 00:02:35.330 regulatory compliance. Exactly. What's fascinating 00:02:35.330 --> 00:02:38.210 here, I think, is understanding the true criticality 00:02:38.210 --> 00:02:41.400 of that infrastructure. CRL isn't just generating 00:02:41.400 --> 00:02:44.020 data points. They are generating the precise, 00:02:44.360 --> 00:02:47.300 standardized data packages. You know, the toxicology 00:02:47.300 --> 00:02:49.759 reports, the safety assessments that drug developers 00:02:49.759 --> 00:02:52.460 absolutely must have to submit their investigational 00:02:52.460 --> 00:02:54.699 new drug application. The IND applications, right, 00:02:54.800 --> 00:02:58.219 to the FDA. To the US FDA, to the EMA, in Europe, 00:02:58.280 --> 00:03:01.060 everywhere. Our mission today is really to trace 00:03:01.060 --> 00:03:04.889 this journey. How did a single entity grow from, 00:03:04.930 --> 00:03:06.870 I mean, the humblest of beginnings to become 00:03:06.870 --> 00:03:09.810 so deeply and so indispensably embedded in the 00:03:09.810 --> 00:03:12.509 entire life sciences pipeline, covering everything 00:03:12.509 --> 00:03:14.530 from initial target discovery all the way to 00:03:14.530 --> 00:03:16.569 cutting edge cell and gene therapy manufacturing? 00:03:16.969 --> 00:03:19.289 That transition from humble to indispensable 00:03:19.289 --> 00:03:22.030 is genuinely one of the most remarkable corporate 00:03:22.030 --> 00:03:25.819 stories of the last century. So to start, we 00:03:25.819 --> 00:03:28.199 have to look all the way back to 1947 and the 00:03:28.199 --> 00:03:31.000 founder, a man named Henry Foster. Henry Foster 00:03:31.000 --> 00:03:34.080 was a young veterinarian, and his decision in 00:03:34.080 --> 00:03:36.939 1947 was just a masterclass in identifying a 00:03:36.939 --> 00:03:39.419 niche that everyone needed, but nobody was supplying 00:03:39.419 --> 00:03:42.080 reliably. He set up a one -person laboratory 00:03:42.080 --> 00:03:44.860 in Boston, geographically located to overlook 00:03:44.860 --> 00:03:47.280 the Charles River. Which naturally gave the company 00:03:47.280 --> 00:03:49.139 its name. Of course. And the inventory, this 00:03:49.139 --> 00:03:50.659 is the detail that really hooks you. He didn't 00:03:50.659 --> 00:03:53.039 start with... You know, cutting edge analytical 00:03:53.039 --> 00:03:55.000 chemistry equipment or anything like that. Not 00:03:55.000 --> 00:03:58.080 at all. He purchased 1 ,000 rat cages from a 00:03:58.080 --> 00:04:01.199 Virginia farm. He started simply as a dedicated 00:04:01.199 --> 00:04:04.439 supplier of research animals. Exactly. And this 00:04:04.439 --> 00:04:06.620 immediately defines the company's original core 00:04:06.620 --> 00:04:10.259 business, supplying local researchers with standardized, 00:04:10.379 --> 00:04:14.120 reliable laboratory animals. And it sounds incredibly 00:04:14.120 --> 00:04:17.180 basic, maybe even mundane. Yeah, a guy with some 00:04:17.180 --> 00:04:20.220 rats. Right. But you have to place yourself in 00:04:20.220 --> 00:04:22.680 the context of the pharmaceutical world immediately 00:04:22.680 --> 00:04:25.540 following World War II. Okay, explain that necessity. 00:04:25.759 --> 00:04:27.319 Because for someone who might not understand 00:04:27.319 --> 00:04:30.620 the biology, why was a reliable rat so essential? 00:04:31.000 --> 00:04:33.339 It was everything. I mean, this was the era of 00:04:33.339 --> 00:04:35.819 explosive growth in modern pharmaceuticals. You 00:04:35.819 --> 00:04:37.839 had antibiotics, early treatments for chronic 00:04:37.839 --> 00:04:40.279 diseases. And this is the key, the beginning 00:04:40.279 --> 00:04:43.160 of rigorous regulatory scrutiny. Drug testing 00:04:43.160 --> 00:04:46.079 requires repeatable results. If you test a new 00:04:46.079 --> 00:04:48.240 compound in a group of lab animals and those 00:04:48.240 --> 00:04:50.160 animals are all genetically varied or worse, 00:04:50.279 --> 00:04:52.279 if they carry different undiagnosed background 00:04:52.279 --> 00:04:54.540 pathogens. We call those dirty models. Exactly. 00:04:54.720 --> 00:04:56.579 Dirty models. Your results will be inconsistent, 00:04:56.920 --> 00:04:59.819 unreliable, and ultimately useless for a regulatory 00:04:59.819 --> 00:05:02.360 submission. You're essentially introducing way 00:05:02.360 --> 00:05:05.500 too many variables into the experiment. Precisely. 00:05:05.660 --> 00:05:08.079 Henry Foster's insight was that pharmaceutical 00:05:08.079 --> 00:05:10.740 companies needed models that were identical, 00:05:11.019 --> 00:05:14.000 predictable, and certified disease -free. He 00:05:14.000 --> 00:05:17.040 wasn't just selling rats. He was selling standardization 00:05:17.040 --> 00:05:20.259 and quality control. I see. His ability to provide 00:05:20.259 --> 00:05:22.879 that consistent, high -quality research model 00:05:22.879 --> 00:05:25.680 laid the essential groundwork for every single 00:05:25.680 --> 00:05:27.680 sophisticated service the company would offer 00:05:27.680 --> 00:05:31.019 later. Standardization was literally embedded 00:05:31.019 --> 00:05:34.139 in their DNA, in their supply chain, from day 00:05:34.139 --> 00:05:36.319 one. So following this foundational work, the 00:05:36.319 --> 00:05:40.019 company begins its expansion. In 1955, they relocated 00:05:40.019 --> 00:05:41.740 their headquarters to Wilmington, Massachusetts, 00:05:41.939 --> 00:05:44.660 where they are still based today. Then, just 00:05:44.660 --> 00:05:48.620 11 years later, in 1966, we see CRL's first acknowledgement 00:05:48.620 --> 00:05:51.160 that research was going global. They opened an 00:05:51.160 --> 00:05:53.519 animal production facility in France. And that 00:05:53.519 --> 00:05:57.069 1966 move is highly significant. It demonstrated 00:05:57.069 --> 00:05:59.430 an early recognition that drug discovery wasn't 00:05:59.430 --> 00:06:01.410 just confined to the U .S. Northeast. It's not 00:06:01.410 --> 00:06:03.889 just a Boston thing anymore. Not at all. If their 00:06:03.889 --> 00:06:05.870 pharmaceutical clients were expanding operations 00:06:05.870 --> 00:06:09.189 into Europe, CRL had to ensure those researchers 00:06:09.189 --> 00:06:12.209 had immediate access to the exact same standardized 00:06:12.209 --> 00:06:15.230 models they were using back home. It was all 00:06:15.230 --> 00:06:18.490 about ensuring global continuity of testing protocols. 00:06:18.870 --> 00:06:21.370 But the real technical leap, the move from being 00:06:21.370 --> 00:06:23.910 a simple supplier to a high science partner, 00:06:24.089 --> 00:06:27.800 that came in 1981. This is when the company implemented 00:06:27.800 --> 00:06:30.660 the first commercial comprehensive genetic monitoring 00:06:30.660 --> 00:06:33.379 program. Okay, let's unpack this for the listener. 00:06:33.579 --> 00:06:37.160 Why is genetic monitoring for a mouse or a rat 00:06:37.160 --> 00:06:40.279 such a landmark revenue -driving event? Well, 00:06:40.360 --> 00:06:41.879 it's the difference between selling a commodity 00:06:41.879 --> 00:06:44.959 and selling a guaranteed scientific tool. Genetic 00:06:44.959 --> 00:06:47.139 monitoring is quality control raised to the highest 00:06:47.139 --> 00:06:49.970 possible level. By rigorously monitoring the 00:06:49.970 --> 00:06:52.250 genetic makeup of their animal colonies, they 00:06:52.250 --> 00:06:54.050 were guaranteeing to the pharmaceutical researcher 00:06:54.050 --> 00:06:56.850 that the model was genetically homogenous. Meaning, 00:06:57.029 --> 00:06:59.310 if a drug had a different effect on Model A versus 00:06:59.310 --> 00:07:01.769 Model B, that difference could only be attributed 00:07:01.769 --> 00:07:04.310 to the drug itself and not some natural genetic 00:07:04.310 --> 00:07:07.230 variation in the test subject. Exactly. This 00:07:07.230 --> 00:07:09.829 drastically reduces the noise in the data. For 00:07:09.829 --> 00:07:11.870 a pharma company that is spending potentially 00:07:11.870 --> 00:07:14.250 hundreds of millions of dollars to test a compound, 00:07:14.490 --> 00:07:16.870 they need that certainty. Of course. So this 00:07:16.870 --> 00:07:20.129 move back in 1981 proved that CRL was focused 00:07:20.129 --> 00:07:22.589 on repeatable science, and it bolstered their 00:07:22.589 --> 00:07:25.149 credibility immensely with regulatory bodies 00:07:25.149 --> 00:07:28.149 who rely on reproducible data. It transformed 00:07:28.149 --> 00:07:30.990 them from just a vendor of mice into a supplier 00:07:30.990 --> 00:07:33.829 of validated essential research platforms. The 00:07:33.829 --> 00:07:36.490 1980s also brought a brief but fascinating ownership 00:07:36.490 --> 00:07:39.649 change. In 1984, Charles River was acquired by 00:07:39.649 --> 00:07:41.790 Bausch & Lomb, which really speaks to the recognized 00:07:41.790 --> 00:07:45.089 value of these standardized essential services. 00:07:45.350 --> 00:07:47.209 It does. The acquisition was a sign that the 00:07:47.209 --> 00:07:49.629 market was consolidating and that a major player 00:07:49.629 --> 00:07:52.629 like Bausch & Lomb recognized the stable, necessary 00:07:52.629 --> 00:07:56.110 revenue stream CRL provided. But the story continues 00:07:56.110 --> 00:07:58.250 with this powerful founder family intervention. 00:07:58.490 --> 00:08:01.709 Right, with Jim Foster. Yes. In the 1990s, Jim 00:08:01.709 --> 00:08:04.329 Foster, Henry's son, led a management buyout 00:08:04.329 --> 00:08:06.750 to acquire Charles River back from Bausch & Lomb. 00:08:06.970 --> 00:08:10.069 This return to private then public journey, which 00:08:10.069 --> 00:08:12.089 culminated in their public listing on the NYSE, 00:08:12.250 --> 00:08:15.930 is classic business history. It shows that founder 00:08:15.930 --> 00:08:17.910 -led commitment to capitalizing on the explosive 00:08:17.910 --> 00:08:21.360 growth of the outsourced CRO market. And during 00:08:21.360 --> 00:08:23.660 this period of ownership transition and eventual 00:08:23.660 --> 00:08:26.639 public listing, CRL dramatically expanded its 00:08:26.639 --> 00:08:28.879 technical capabilities. It wasn't just about 00:08:28.879 --> 00:08:31.540 breeding standardized models anymore. In 1988, 00:08:31.860 --> 00:08:34.299 they began creating transgenic mice and rats. 00:08:34.580 --> 00:08:36.519 And that is a fundamental expansion in technical 00:08:36.519 --> 00:08:39.059 scope and commercial value. Transgenic models 00:08:39.059 --> 00:08:41.679 are animals whose genetic material has been specifically 00:08:41.679 --> 00:08:44.429 altered. How so? They're altered to carry certain 00:08:44.429 --> 00:08:47.570 genes or exhibit specific human conditions. For 00:08:47.570 --> 00:08:49.169 example, they might carry the human gene for 00:08:49.169 --> 00:08:52.370 a specific cancer or exhibit symptoms similar 00:08:52.370 --> 00:08:55.210 to Alzheimer's or Parkinson's disease. So instead 00:08:55.210 --> 00:08:57.649 of just using a generic rodent to test for general 00:08:57.649 --> 00:09:00.490 toxicity, you are now using a tailor -made model 00:09:00.490 --> 00:09:03.659 that can mimic a human disease. Precisely. This 00:09:03.659 --> 00:09:06.139 elevates Charles River from a supplier of generic 00:09:06.139 --> 00:09:08.600 models to a provider of highly sophisticated 00:09:08.600 --> 00:09:12.419 disease -specific research tools. And that saves 00:09:12.419 --> 00:09:15.039 researchers years of trying to establish their 00:09:15.039 --> 00:09:18.039 own testing protocols. It accelerates the discovery 00:09:18.039 --> 00:09:20.500 phase immensely. And this focus on specialized 00:09:20.500 --> 00:09:22.820 testing and safety assessment continued into 00:09:22.820 --> 00:09:25.639 the 1990s when they began in vitro endotoxin 00:09:25.639 --> 00:09:28.600 testing. This is a major pivot toward regulatory 00:09:28.600 --> 00:09:32.259 compliance and safety diagnostics. Endotoxins 00:09:32.259 --> 00:09:35.129 are. They're toxic compounds found in the outer 00:09:35.129 --> 00:09:37.409 membrane of certain bacteria. And if they get 00:09:37.409 --> 00:09:39.350 into the human bloodstream, they can cause dangerous 00:09:39.350 --> 00:09:42.429 fevers, organ failure, even septic shock. So 00:09:42.429 --> 00:09:44.830 the FDA requires testing for this. Oh, absolutely. 00:09:45.029 --> 00:09:48.389 The FDA requires that all injectable drugs, intravenous 00:09:48.389 --> 00:09:50.710 solutions, and implanted medical devices must 00:09:50.710 --> 00:09:52.870 be tested for endotoxins before they can be used. 00:09:52.990 --> 00:09:55.509 No exceptions. Which is where CRL's microbial 00:09:55.509 --> 00:09:58.370 testing services come in. Correct. They use a 00:09:58.370 --> 00:10:00.129 substance derived from the blood of horseshoe 00:10:00.129 --> 00:10:02.850 crabs. It's called the limulus amebocyte lysate 00:10:02.850 --> 00:10:06.250 test, or LAL test, to detect even trace amounts 00:10:06.250 --> 00:10:09.629 of these endotoxins. By offering this critical 00:10:09.629 --> 00:10:12.009 in vitro, you know, in the lab dish, testing, 00:10:12.309 --> 00:10:15.570 CRL solidified its role as an indispensable partner 00:10:15.570 --> 00:10:17.990 for meeting mandatory safety requirements across 00:10:17.990 --> 00:10:20.309 the entire medical industry, not just drug development. 00:10:20.789 --> 00:10:23.009 So the foundation is the standardized research 00:10:23.009 --> 00:10:25.429 model, but the structure built on top of it is 00:10:25.429 --> 00:10:28.450 just vast. If we look at CRL's modern operations, 00:10:28.750 --> 00:10:31.490 they are a massive, full -service contract research 00:10:31.490 --> 00:10:34.409 organization. What are the key pillars of their 00:10:34.409 --> 00:10:36.879 portfolio today? You can break it down into three 00:10:36.879 --> 00:10:39.279 main integrated pillars. First, they still have 00:10:39.279 --> 00:10:40.879 research models. That's the traditional foundation. 00:10:41.120 --> 00:10:43.519 But now they're primarily complex, transgenic, 00:10:43.519 --> 00:10:45.980 specialized models. Second, they have safety 00:10:45.980 --> 00:10:48.539 assessment. This involves the necessary long 00:10:48.539 --> 00:10:50.440 -term toxicology studies that are crucial for 00:10:50.440 --> 00:10:53.139 any regulatory submission. And third, they offer 00:10:53.139 --> 00:10:55.919 microbial testing services built on that endotoxin 00:10:55.919 --> 00:10:58.039 testing expertise, ensuring product safety in 00:10:58.039 --> 00:11:00.139 sterile manufacturing environments. I noticed 00:11:00.139 --> 00:11:02.700 a specific term in the outline that signals the 00:11:02.700 --> 00:11:05.590 next level of standardization. preconditioning 00:11:05.590 --> 00:11:10.029 services, introduced in 2005. What does preconditioning 00:11:10.029 --> 00:11:12.149 entail, and how is it more advanced than just 00:11:12.149 --> 00:11:15.029 supplying a standardized animal? Preconditioning 00:11:15.029 --> 00:11:17.549 is the next logical step in efficiency and reducing 00:11:17.549 --> 00:11:20.190 variability. It means the animals are delivered 00:11:20.190 --> 00:11:23.049 to the client already study -ready. What does 00:11:23.049 --> 00:11:25.090 that mean, study -ready? Well, for instance, 00:11:25.309 --> 00:11:27.730 if a study requires the model to be on a highly 00:11:27.730 --> 00:11:30.590 specific, low -fat diet for three weeks before 00:11:30.590 --> 00:11:33.330 the compound is administered, CRL performs that 00:11:33.330 --> 00:11:35.360 preconditioning. in their own highly controlled 00:11:35.360 --> 00:11:37.519 facility. So the customer doesn't have to waste 00:11:37.519 --> 00:11:39.899 time and resources acclimating the animals and 00:11:39.899 --> 00:11:41.559 hoping their internal conditions are precisely 00:11:41.559 --> 00:11:44.679 the same every single time. Exactly. It guarantees 00:11:44.679 --> 00:11:46.580 the model is ready to receive the experimental 00:11:46.580 --> 00:11:49.759 compound immediately upon arrival. It eliminates 00:11:49.759 --> 00:11:52.080 external variables, saves the client crucial 00:11:52.080 --> 00:11:55.320 time, and maintains the rigor that regulators 00:11:55.320 --> 00:11:58.360 absolutely demand. It's all about selling guaranteed 00:11:58.360 --> 00:12:01.750 quality and guaranteed speed. This level of institutional 00:12:01.750 --> 00:12:04.990 credibility, built on decades of standardization, 00:12:05.210 --> 00:12:07.990 led to partnerships at the highest levels. In 00:12:07.990 --> 00:12:12.250 2008, CRL signed a landmark 10 -year contract 00:12:12.250 --> 00:12:14.730 with the National Cancer Institute, the NCI, 00:12:14.809 --> 00:12:17.029 and opened a facility in Frederick, Maryland. 00:12:17.289 --> 00:12:20.649 That 10 -year NCI contract is the ultimate proof 00:12:20.649 --> 00:12:24.820 of concept for their standardization model. The 00:12:24.820 --> 00:12:27.480 NCI, one of the most rigorous scientific institutions 00:12:27.480 --> 00:12:30.779 in the world, was outsourcing a massive long 00:12:30.779 --> 00:12:34.440 -term need to CRL. Wow. This move confirmed that 00:12:34.440 --> 00:12:36.759 Charles River had successfully transitioned from 00:12:36.759 --> 00:12:39.399 being merely a vendor to an institutional scientific 00:12:39.399 --> 00:12:42.059 partner, trusted with the infrastructure underlying 00:12:42.059 --> 00:12:45.120 critical government research. At that point, 00:12:45.139 --> 00:12:47.019 they had become indispensable. That transition 00:12:47.019 --> 00:12:49.320 to a critical partner really paved the way for 00:12:49.320 --> 00:12:51.600 the company's explosive 21st century growth. 00:12:51.759 --> 00:12:53.419 And this is where we have to talk about mergers 00:12:53.419 --> 00:12:55.480 and acquisitions. Here's where it gets really 00:12:55.480 --> 00:12:58.360 interesting, because CRL did not just grow organically 00:12:58.360 --> 00:13:01.039 by selling more mice. No, not at all. They built 00:13:01.039 --> 00:13:04.159 a behemoth through relentless, highly strategic 00:13:04.159 --> 00:13:06.820 acquisitions. We need to analyze those deals 00:13:06.820 --> 00:13:09.080 to understand the strategic pivots they were 00:13:09.080 --> 00:13:11.659 making. The M &A strategy has been the core driver 00:13:11.659 --> 00:13:14.179 of their scale and complexity. You can really 00:13:14.179 --> 00:13:17.340 map CRL's evolution through three strategic phases 00:13:17.340 --> 00:13:20.360 of acquisition. The early phase, from about 1988 00:13:20.360 --> 00:13:23.980 to 2000, that was focused on diversifying the 00:13:23.980 --> 00:13:26.000 research model portfolio and building out those 00:13:26.000 --> 00:13:28.080 essential diagnostic and testing capabilities. 00:13:28.480 --> 00:13:30.740 Okay, so what were the key deals in that foundational 00:13:30.740 --> 00:13:33.460 M &A period? Well, they acquired a company called 00:13:33.460 --> 00:13:36.220 Specific Pathogen Antigen -Free Avian Services, 00:13:36.539 --> 00:13:39.440 or SPIFES. which diversified their research models 00:13:39.440 --> 00:13:42.159 beyond rodents into avian species. Into birds. 00:13:42.399 --> 00:13:44.960 Into birds, yes. Crucially, they also acquired 00:13:44.960 --> 00:13:47.659 serologic diagnostic services from Merck, Sharp, 00:13:47.840 --> 00:13:50.159 and Dome, immediately bolstering their testing 00:13:50.159 --> 00:13:53.259 expertise, and later buying EndoSafe Inc. and 00:13:53.259 --> 00:13:57.090 Sierra Biomedical between 1996 and 2000. That 00:13:57.090 --> 00:13:58.830 solidified their internal testing infrastructure, 00:13:59.289 --> 00:14:02.350 particularly around endotoxin testing and specialized 00:14:02.350 --> 00:14:04.690 toxicology. So they were ensuring they owned 00:14:04.690 --> 00:14:07.129 the entire quality control vertical. Precisely. 00:14:07.129 --> 00:14:09.049 They were locking it all down. The next phase, 00:14:09.149 --> 00:14:11.889 then, was the major leap, the transition from 00:14:11.889 --> 00:14:14.809 being a supplier and a specialized tester to 00:14:14.809 --> 00:14:18.870 a true full -service CRO. And that starts primarily 00:14:18.870 --> 00:14:22.889 with the 2003 merger with Inveresk. The Inveresk 00:14:22.889 --> 00:14:25.289 merger was a dramatic international expansion. 00:14:25.789 --> 00:14:28.549 Inverex was a UK -based company specializing 00:14:28.549 --> 00:14:30.750 in clinical research and preclinical testing, 00:14:30.950 --> 00:14:33.850 primarily based in Scotland. The merger provided 00:14:33.850 --> 00:14:36.549 CRL with a massive international footprint outside 00:14:36.549 --> 00:14:39.389 the US, and more importantly, a much broader 00:14:39.389 --> 00:14:42.190 service offering. It included managing complex 00:14:42.190 --> 00:14:44.409 studies, not just supplying the components for 00:14:44.409 --> 00:14:46.120 them. You mentioned, though, that the integration 00:14:46.120 --> 00:14:48.960 wasn't entirely smooth. They later divested part 00:14:48.960 --> 00:14:51.360 of that acquisition, selling the Edinburgh Clinical 00:14:51.360 --> 00:14:53.539 Services Division to Quotient Buyer Research 00:14:53.539 --> 00:14:57.320 in 2009. That suggests a kind of strategic tightening. 00:14:57.639 --> 00:14:59.679 It does. And this is where we can introduce some 00:14:59.679 --> 00:15:02.139 constructive friction into the analysis. Selling 00:15:02.139 --> 00:15:03.879 the Clinical Services Division could be interpreted 00:15:03.879 --> 00:15:05.919 in a couple of ways. Either they struggled to 00:15:05.919 --> 00:15:08.240 integrate the very different operational model 00:15:08.240 --> 00:15:11.360 of clinical trials, or it signaled a strategic 00:15:11.360 --> 00:15:14.750 decision to focus exclusively on their core competence, 00:15:14.929 --> 00:15:18.110 which was the earlier preclinical stage. Ultimately, 00:15:18.710 --> 00:15:20.649 they double down on being the best at everything 00:15:20.649 --> 00:15:23.850 before human trials begin. And that's often where 00:15:23.850 --> 00:15:26.529 the highest regulatory risk lies. And that focus 00:15:26.529 --> 00:15:29.149 on early -stage integration accelerated dramatically 00:15:29.149 --> 00:15:32.029 in 2014 with the acquisitions of Argenta and 00:15:32.029 --> 00:15:35.389 BioFocus. This acquisition seems key to understanding 00:15:35.389 --> 00:15:38.570 CRL's modern value proposition. Absolutely key. 00:15:38.690 --> 00:15:40.970 This is what established CRL as a full -service 00:15:40.970 --> 00:15:44.350 early -stage CRO. We need to slow down and define 00:15:44.350 --> 00:15:47.070 the functional significance of their newly integrated 00:15:47.070 --> 00:15:49.730 in vitro and in vivo capabilities. Okay, let's 00:15:49.730 --> 00:15:51.470 clarify that technical distinction for everyone 00:15:51.470 --> 00:15:54.559 listening. In vitro means in glass. It's essentially 00:15:54.559 --> 00:15:57.320 lab -based bench science, the very beginning 00:15:57.320 --> 00:15:59.440 of the process where scientists identify potential 00:15:59.440 --> 00:16:02.440 drug targets and screen thousands of compounds 00:16:02.440 --> 00:16:05.139 in dishes or tubes. And in vivo. In vivo means 00:16:05.139 --> 00:16:07.960 in the living organism, testing those viable 00:16:07.960 --> 00:16:10.139 compounds in their specialized animal models. 00:16:10.379 --> 00:16:14.480 By acquiring both Argenta and BioFocus, CRL could 00:16:14.480 --> 00:16:17.519 offer a seamless, integrated process from the 00:16:17.519 --> 00:16:20.000 moment of target discovery all the way through 00:16:20.000 --> 00:16:22.909 preclinical development. Instead of a pharma 00:16:22.909 --> 00:16:25.230 company having to coordinate between, what, three 00:16:25.230 --> 00:16:27.350 or four different specialized firms to get a 00:16:27.350 --> 00:16:29.450 compound from an initial concept to regulatory 00:16:29.450 --> 00:16:32.450 readiness, they can now just use CRL for that 00:16:32.450 --> 00:16:35.590 entire early stage journey. Yes. That efficiency 00:16:35.590 --> 00:16:38.370 must be immensely valuable. It creates a massive 00:16:38.370 --> 00:16:40.669 economic moat. It reduces administrative overhead 00:16:40.669 --> 00:16:42.509 for the client. It streamlines data transfer. 00:16:42.649 --> 00:16:45.429 And it ensures consistent quality control across 00:16:45.429 --> 00:16:48.190 all stages, which is priceless when you're facing 00:16:48.190 --> 00:16:50.799 rigorous regulatory scrutiny. Now, while the 00:16:50.799 --> 00:16:52.940 strategy generally involved swallowing up smaller 00:16:52.940 --> 00:16:55.419 firms, there was one major public failure in 00:16:55.419 --> 00:16:58.399 their expansion strategy. The failed 2010 attempt 00:16:58.399 --> 00:17:01.559 to acquire Wuxi Pharma Tech. This really highlights 00:17:01.559 --> 00:17:03.679 the limits of expansion when you face shareholder 00:17:03.679 --> 00:17:06.880 resistance. The attempted Wixi acquisition was 00:17:06.880 --> 00:17:10.119 an attempt at a giant defining strategic leap. 00:17:10.519 --> 00:17:13.119 It was aimed at penetrating the rapidly growing 00:17:13.119 --> 00:17:17.319 Chinese CRO market and achieving just unparalleled 00:17:17.319 --> 00:17:20.430 global scale in one single go. But the deal was 00:17:20.430 --> 00:17:23.410 withdrawn after intense investor backlash. A 00:17:23.410 --> 00:17:25.950 major merger torpedoed by their own shareholders. 00:17:26.130 --> 00:17:28.130 That's pretty rare. Was this simply about the 00:17:28.130 --> 00:17:30.750 price tag or were investors fundamentally afraid 00:17:30.750 --> 00:17:34.869 of acquiring a massive China -based CRO and, 00:17:35.069 --> 00:17:37.329 you know, the integration or regulatory headaches 00:17:37.329 --> 00:17:39.529 that might follow? It was a combination of factors, 00:17:39.630 --> 00:17:41.930 but the investor concern went way beyond just 00:17:41.930 --> 00:17:44.910 valuation. Prominent large investors, including 00:17:44.910 --> 00:17:47.269 relational investors, J &R Partners and Neuberger 00:17:47.269 --> 00:17:50.309 Berman, they opposed it vociferously. The proxy 00:17:50.309 --> 00:17:52.670 advisory firm Risk Metrics also recommended a 00:17:52.670 --> 00:17:55.210 no vote. Wow. The core issue was perceived integration 00:17:55.210 --> 00:17:58.250 risk combined with strategic dilution. Investors 00:17:58.250 --> 00:18:00.390 worried that a massive cross -border merger involving 00:18:00.390 --> 00:18:03.230 such complex, specialized regulatory environments 00:18:03.230 --> 00:18:06.009 would destabilize CRL's core business, which 00:18:06.009 --> 00:18:07.849 relied on rock -solid, predictable execution. 00:18:08.269 --> 00:18:11.130 So the investors were prioritizing stability 00:18:11.130 --> 00:18:14.190 and controlled growth over this high -risk, high 00:18:14.190 --> 00:18:17.670 -reward leap into total global dominance. Precisely. 00:18:17.920 --> 00:18:20.079 It showed the limits of the expansion strategy. 00:18:20.400 --> 00:18:23.500 Despite CRL's executive drive for massive immediate 00:18:23.500 --> 00:18:26.079 scale, the shareholder structure demanded a more 00:18:26.079 --> 00:18:28.619 controlled approach. And we can see this enforced 00:18:28.619 --> 00:18:30.759 strategy shift in their incremental approach 00:18:30.759 --> 00:18:32.480 to the Chinese market immediately afterward. 00:18:32.799 --> 00:18:34.960 The source material notes that CRL successfully 00:18:34.960 --> 00:18:38.500 acquired Vital River in the 2008 -2013 period, 00:18:38.759 --> 00:18:41.220 which expanded their research models and services 00:18:41.220 --> 00:18:43.920 portfolio into the Chinese drug development market, 00:18:44.119 --> 00:18:46.859 but on a more palatable incremental scale. That's 00:18:46.859 --> 00:18:49.099 a brilliant connection. The failure of the Waxee 00:18:49.099 --> 00:18:52.059 merger forced CRL to execute the same global 00:18:52.059 --> 00:18:54.839 expansion strategy through smaller, more manageable 00:18:54.839 --> 00:18:57.640 acquisitions. It was a slow but ultimately more 00:18:57.640 --> 00:19:00.680 successful path for shareholder confidence. This 00:19:00.680 --> 00:19:03.079 period also saw them acquiring specialized expertise 00:19:03.079 --> 00:19:06.019 through purchases like New Lab BioQuality AG, 00:19:06.480 --> 00:19:09.640 MIR Preclinical Services, Piedmont Research Center, 00:19:09.819 --> 00:19:13.200 Cerebrocon, and Acugenics. all designed to broaden 00:19:13.200 --> 00:19:15.140 their existing technical services and geographic 00:19:15.140 --> 00:19:18.460 reach in a much more controlled manner. So as 00:19:18.460 --> 00:19:21.019 CRL entered the mid -2010s, they clearly had 00:19:21.019 --> 00:19:23.339 the shareholder mandate to execute large strategic 00:19:23.339 --> 00:19:26.599 deals, but they were focusing primarily on solidifying 00:19:26.599 --> 00:19:28.680 their toxicology and safety assessment leadership. 00:19:29.259 --> 00:19:31.660 The cash flow required for these acquisitions 00:19:31.660 --> 00:19:34.240 is just staggering. The numbers really illustrate 00:19:34.240 --> 00:19:36.660 the value of consolidating this niche specialized 00:19:36.660 --> 00:19:39.480 infrastructure. Yeah. In 2016, they acquired 00:19:39.480 --> 00:19:42.140 Will Research for approximately $585 million. 00:19:42.559 --> 00:19:45.690 Wow. In 2018, they bought MPI Research for approximately 00:19:45.690 --> 00:19:49.569 $800 billion. And in 2019, they acquired Cytics 00:19:49.569 --> 00:19:52.650 Lab for roughly $500 million. These purchases 00:19:52.650 --> 00:19:55.950 were defensive, strategic, basically swallowing 00:19:55.950 --> 00:19:59.049 competitors to gain immense scale, crucial toxicology 00:19:59.049 --> 00:20:01.809 expertise, and key geographic presence in Europe 00:20:01.809 --> 00:20:04.529 and North America. And this scale creates an 00:20:04.529 --> 00:20:07.390 economic moat. If you are a pharmaceutical company, 00:20:07.529 --> 00:20:10.450 it's just safer and easier to go with the vendor 00:20:10.450 --> 00:20:13.009 who has absorbed all the expertise and has the 00:20:13.009 --> 00:20:14.910 scale to manage your entire pipeline, right? 00:20:15.029 --> 00:20:17.609 Absolutely. They are selling standardization, 00:20:17.690 --> 00:20:20.339 but they're also selling risk reduction. When 00:20:20.339 --> 00:20:22.160 you work with CRL, you're buying their proven 00:20:22.160 --> 00:20:24.519 track record of getting safety data through regulatory 00:20:24.519 --> 00:20:27.579 hurdles. That is worth hundreds of millions of 00:20:27.579 --> 00:20:29.740 dollars to a pharma client. But the most crucial 00:20:29.740 --> 00:20:32.220 forward -looking strategic pivot, the one that 00:20:32.220 --> 00:20:35.180 really defines the future of CRL, happened between 00:20:35.180 --> 00:20:39.670 2019 and 2021. the deep dive into cell and gene 00:20:39.670 --> 00:20:43.190 therapy or CGT. This wasn't just acquiring another 00:20:43.190 --> 00:20:46.289 tox lab. This was a complete repositioning. This 00:20:46.289 --> 00:20:49.829 is the $1 .5 billion question. Why did they spend 00:20:49.829 --> 00:20:53.880 so much so quickly to enter the CGT space? The 00:20:53.880 --> 00:20:55.880 answer lies in future -proofing the business. 00:20:56.180 --> 00:20:58.539 The pharmaceutical industry is moving away from 00:20:58.539 --> 00:21:01.039 traditional small molecule drugs and toward advanced 00:21:01.039 --> 00:21:02.819 therapy piece treatments that use living cells 00:21:02.819 --> 00:21:05.200 or modified genetic material. Gene therapy. Gene 00:21:05.200 --> 00:21:07.259 therapy. And these are exponentially more complex 00:21:07.259 --> 00:21:10.380 to test and critically to manufacture. So CRL 00:21:10.380 --> 00:21:12.460 realized that if they didn't become indispensable 00:21:12.460 --> 00:21:15.579 in CGT, they would miss the next major wave of 00:21:15.579 --> 00:21:18.119 drug development. Exactly. They needed to position 00:21:18.119 --> 00:21:20.759 themselves as the necessary scientific partner 00:21:20.759 --> 00:21:24.089 for these highly specialized complex. And this 00:21:24.089 --> 00:21:27.670 required buying expertise and, crucially, buying 00:21:27.670 --> 00:21:29.930 specialized manufacturing capacity. Detail the 00:21:29.930 --> 00:21:32.049 acquisitions that drove this monumental pivot 00:21:32.049 --> 00:21:34.289 for us. They started by focusing on the sell 00:21:34.289 --> 00:21:37.029 side of things. In December 2019, they acquired 00:21:37.029 --> 00:21:40.849 Hemacare for $380 million, followed by Soliero 00:21:40.849 --> 00:21:43.910 in 2012. These companies focus on the highly 00:21:43.910 --> 00:21:47.009 specific sourcing, collection, and handling of 00:21:47.009 --> 00:21:49.490 critical cellular material used in cell therapies, 00:21:49.730 --> 00:21:51.829 which are often customized, patient -specific 00:21:51.829 --> 00:21:54.190 treatments. Then came the real game changers 00:21:54.190 --> 00:21:56.710 in 2021, focusing on the gene side. Correct. 00:21:56.829 --> 00:21:59.970 In February 2021, they acquired Cognate Bioservices 00:21:59.970 --> 00:22:04.410 for $875 million. The stated goal was explicit, 00:22:04.730 --> 00:22:07.710 to create a premier scientific partner for cell 00:22:07.710 --> 00:22:09.710 and gene therapy development. So they weren't 00:22:09.710 --> 00:22:12.420 hiding their ambition. Not at all. Cognate brought 00:22:12.420 --> 00:22:14.500 immediate expertise in the complex development 00:22:14.500 --> 00:22:17.599 and, more importantly, the manufacturing of these 00:22:17.599 --> 00:22:19.339 advanced therapies. And they followed that up 00:22:19.339 --> 00:22:23.640 in May 2021 with Vigene Biosciences. Vigene Biosciences, 00:22:23.779 --> 00:22:28.119 acquired for $292 .5 million, is a dedicated 00:22:28.119 --> 00:22:30.559 gene therapy contract development and manufacturing 00:22:30.559 --> 00:22:34.700 organization, or CDMO. This is the ultimate vertical 00:22:34.700 --> 00:22:37.900 integration. A CDMO? Explain that. Gene therapies 00:22:37.900 --> 00:22:40.789 rely on something called viral vectors. essentially 00:22:40.789 --> 00:22:43.150 deactivated viruses that deliver the therapeutic 00:22:43.150 --> 00:22:46.309 gene into the patient's cells. Manufacturing 00:22:46.309 --> 00:22:48.269 these viral vectors is incredibly difficult, 00:22:48.410 --> 00:22:51.349 highly regulated, and capacity was scarce globally, 00:22:51.589 --> 00:22:54.710 especially after the pandemic. So CRL moved beyond 00:22:54.710 --> 00:22:57.089 testing and assessment. They are now involved 00:22:57.089 --> 00:22:59.109 in the actual making of the complex components 00:22:59.109 --> 00:23:01.869 required for gene therapies. That introduces 00:23:01.869 --> 00:23:04.349 a potential complexity, though. Does being the 00:23:04.349 --> 00:23:06.789 manufacturer and the tester of a product create 00:23:06.789 --> 00:23:09.480 a kind of conflict of interest? That is a critical 00:23:09.480 --> 00:23:11.720 insight for the listener. The industry relies 00:23:11.720 --> 00:23:14.819 on firewalls, transparency, and strict regulatory 00:23:14.819 --> 00:23:17.680 oversight to manage that tension. But strategically, 00:23:18.079 --> 00:23:21.319 for CRL, the advantage is overwhelming. They 00:23:21.319 --> 00:23:24.000 control the vertical supply chain. If a client 00:23:24.000 --> 00:23:26.920 uses CRL to manufacture their viral vector, they 00:23:26.920 --> 00:23:29.380 are highly incentivized to use CRL's specialized 00:23:29.380 --> 00:23:32.539 safety assessment teams who are experts in testing 00:23:32.539 --> 00:23:34.930 products they themselves manufactured. So what 00:23:34.930 --> 00:23:37.230 does this all mean when we synthesize this entire 00:23:37.230 --> 00:23:41.029 century of activity from rat cages to viral vectors? 00:23:41.329 --> 00:23:43.829 It shows CRL transforming in two critical ways. 00:23:44.150 --> 00:23:46.809 First, they built an immense economic moat by 00:23:46.809 --> 00:23:49.170 consolidating all the mandatory preclinical testing 00:23:49.170 --> 00:23:51.750 services. Second, they ensured their longevity 00:23:51.750 --> 00:23:54.509 by investing massive capital into the most complex 00:23:54.509 --> 00:23:57.250 high growth area of medicine. gene and cell therapy 00:23:57.250 --> 00:23:59.769 manufacturing. They're embedding themselves not 00:23:59.769 --> 00:24:01.809 just into the testing phase of medicine, but 00:24:01.809 --> 00:24:04.029 into the actual production and quality control 00:24:04.029 --> 00:24:06.430 of the future generation of drugs. Now that we 00:24:06.430 --> 00:24:09.029 understand how critical Charles River Laboratories 00:24:09.029 --> 00:24:11.730 is to drug safety and development, we have to 00:24:11.730 --> 00:24:14.589 address the dual nature of their business. While 00:24:14.589 --> 00:24:17.150 indispensable for new medicine, they operate 00:24:17.150 --> 00:24:19.630 in a realm that is inherently fraught with public 00:24:19.630 --> 00:24:22.710 scrutiny and ethical challenges, the use of laboratory 00:24:22.710 --> 00:24:25.650 animals. This tension is structural. It's built 00:24:25.650 --> 00:24:28.369 into the business. The current regulatory environment, 00:24:28.529 --> 00:24:30.730 specifically in the U .S. and Europe, mandates 00:24:30.730 --> 00:24:32.990 that certain safety assessments, particularly 00:24:32.990 --> 00:24:36.869 toxicology, must be performed in vivo. In living 00:24:36.869 --> 00:24:39.809 organisms. In living, complex biological systems 00:24:39.809 --> 00:24:43.329 before human trials can begin. The controversy 00:24:43.329 --> 00:24:46.230 arises when that necessary use of animals butts 00:24:46.230 --> 00:24:49.150 up against ethical standards, operational failures, 00:24:49.289 --> 00:24:52.650 and growing public opposition. What are the specific... 00:24:52.880 --> 00:24:55.480 animal species that have been the focus of concern 00:24:55.480 --> 00:24:57.940 in the source material and why those particular 00:24:57.940 --> 00:25:00.880 ones? The focus of concern has consistently centered 00:25:00.880 --> 00:25:03.700 on specific species known for their cognitive 00:25:03.700 --> 00:25:05.980 abilities or their environmental sensitivity. 00:25:06.380 --> 00:25:09.039 We're talking about dogs, primates, and horseshoe 00:25:09.039 --> 00:25:11.660 crabs. Dogs are often used in toxicology studies. 00:25:11.859 --> 00:25:14.099 Primates are crucial for complex neurological 00:25:14.099 --> 00:25:17.259 or immunological studies because of their biological 00:25:17.259 --> 00:25:19.920 similarity to humans. And the horseshoe crab, 00:25:20.019 --> 00:25:22.220 as we've discussed, is used for that vital... 00:25:22.220 --> 00:25:25.140 microbial testing. Let's look at concrete examples 00:25:25.140 --> 00:25:27.200 of this controversy because they really illustrate 00:25:27.200 --> 00:25:30.059 the operational pressures CRL faces across its 00:25:30.059 --> 00:25:32.799 global network. We can trace high profile scrutiny 00:25:32.799 --> 00:25:37.119 back to 2014. CBS News reported on concerns regarding 00:25:37.119 --> 00:25:39.859 poor conditions for research dogs in their Massachusetts 00:25:39.859 --> 00:25:42.759 facilities. These kinds of incidents highlight 00:25:42.759 --> 00:25:45.799 the difficulty of maintaining consistent, impeccable 00:25:45.799 --> 00:25:48.240 care standards across thousands of animals and 00:25:48.240 --> 00:25:51.950 multiple facilities. Then in 2019, Fox News featured 00:25:51.950 --> 00:25:54.509 insights from a former worker, which raised specific 00:25:54.509 --> 00:25:57.089 questions about internal lab practices and the 00:25:57.089 --> 00:25:59.970 level of oversight within a facility. So the 00:25:59.970 --> 00:26:02.490 internal accountability necessary to manage such 00:26:02.490 --> 00:26:05.069 complex environments. And a truly distressing 00:26:05.069 --> 00:26:07.390 incident was reported in 2020 by the Sunday Post. 00:26:07.630 --> 00:26:10.369 It detailed a whistleblower accusation concerning 00:26:10.369 --> 00:26:12.890 safety breaches after animals were killed in 00:26:12.890 --> 00:26:15.549 a horrific sounding incident. They labeled a 00:26:15.549 --> 00:26:19.089 compressor horror. These public disclosures. 00:26:19.400 --> 00:26:21.779 regardless of their immediate resolution, are 00:26:21.779 --> 00:26:24.440 incredibly damaging and underscore the absolute 00:26:24.440 --> 00:26:27.339 need for zero tolerance in facility management. 00:26:27.819 --> 00:26:29.740 And the pressure is certainly not diminishing. 00:26:29.799 --> 00:26:32.180 We see it continuing right up to last year with 00:26:32.180 --> 00:26:35.480 groups like Born Free USA protesting Charles 00:26:35.480 --> 00:26:39.119 River's plan to export 1 ,000 endangered juvenile 00:26:39.119 --> 00:26:41.359 long -tailed macaques to Cambodia for testing 00:26:41.359 --> 00:26:44.740 in 2023. That macaque protest raises the conversation 00:26:44.740 --> 00:26:47.400 beyond just facility management and into global 00:26:47.400 --> 00:26:50.079 conservation politics. The use of primates is 00:26:50.079 --> 00:26:52.220 particularly contagious due to their cognitive 00:26:52.220 --> 00:26:55.180 capacity and their frequently endangered or vulnerable 00:26:55.180 --> 00:26:58.000 status in the wild. Right. remain critical models 00:26:58.000 --> 00:26:59.740 for specific types of cutting -edge research, 00:26:59.880 --> 00:27:02.019 think HIV treatments or advanced neuroscience. 00:27:02.359 --> 00:27:04.619 The scientific necessity is constantly weighed 00:27:04.619 --> 00:27:06.859 against the intense and valid ethical opposition 00:27:06.859 --> 00:27:09.839 from conservation groups worldwide. Let's zoom 00:27:09.839 --> 00:27:12.960 in on a specific biological resource that generates 00:27:12.960 --> 00:27:16.059 controversy but is absolutely central to CRL's 00:27:16.059 --> 00:27:19.119 microbial testing services, the horseshoe crab 00:27:19.119 --> 00:27:22.480 blood issue. The horseshoe crab is, scientifically, 00:27:22.819 --> 00:27:25.319 one of the most remarkable animals on the planet. 00:27:25.460 --> 00:27:28.140 Its ancient blue blood is unique because it contains 00:27:28.140 --> 00:27:31.190 something called Limulus amebysite lysate. Or 00:27:31.190 --> 00:27:34.490 LAL. LAL. Yes, and it clots immediately upon 00:27:34.490 --> 00:27:36.569 contact with even trace amounts of bacterial 00:27:36.569 --> 00:27:40.349 endotoxins. This LAL test is the regulatory gold 00:27:40.349 --> 00:27:43.190 standard used globally in microbial testing to 00:27:43.190 --> 00:27:45.390 guarantee that medical devices and injectable 00:27:45.390 --> 00:27:48.609 drugs are sterile and safe. So while the focus 00:27:48.609 --> 00:27:50.869 is usually on mammals like dogs and primates, 00:27:51.009 --> 00:27:53.369 this tiny marine creature is an indispensable 00:27:53.369 --> 00:27:56.470 component of global drug safety. What is the 00:27:56.470 --> 00:27:58.869 ethical dimension reported in our sources concerning 00:27:58.869 --> 00:28:15.289 its use? This connects CRL's core business safety 00:28:15.289 --> 00:28:17.690 testing directly to broader environmental concerns. 00:28:17.970 --> 00:28:21.549 Exactly. The company, through its EndoSafe subsidiary 00:28:21.549 --> 00:28:24.750 and microbial testing services, is highly reliant 00:28:24.750 --> 00:28:28.049 on this resource. The demand for LAL is immense, 00:28:28.289 --> 00:28:30.529 and it's non -negotiable under current regulatory 00:28:30.529 --> 00:28:33.630 frameworks, but the implications for the sustainability 00:28:33.630 --> 00:28:36.730 of the horseshoe crab species and the environmental 00:28:36.730 --> 00:28:40.000 impact of the harvesting process. These are significant 00:28:40.000 --> 00:28:42.900 external pressures. This forces companies like 00:28:42.900 --> 00:28:46.140 CRL to navigate the fine line between providing 00:28:46.140 --> 00:28:49.059 absolutely critical human safety testing and 00:28:49.059 --> 00:28:51.990 ensuring ecological responsibility. So given 00:28:51.990 --> 00:28:55.089 this persistent ethical scrutiny from whistleblower 00:28:55.089 --> 00:28:57.890 claims to conservation protests, how has the 00:28:57.890 --> 00:28:59.970 company responded? How did they address the structural 00:28:59.970 --> 00:29:02.349 tension within their business model? The source 00:29:02.349 --> 00:29:04.609 material provides the counter -context by noting 00:29:04.609 --> 00:29:06.690 the company's internal initiative, which they 00:29:06.690 --> 00:29:09.430 launched all the way back in 2002, the Humane 00:29:09.430 --> 00:29:11.410 Care Imperative. Detail that initiative for us. 00:29:11.470 --> 00:29:13.990 Was it a PR move or was it a necessary operational 00:29:13.990 --> 00:29:17.259 requirement? I think it had to be both. The Humane 00:29:17.259 --> 00:29:20.400 Care Imperative was explicitly designed to raise 00:29:20.400 --> 00:29:23.579 awareness and train employees on animal welfare's 00:29:23.579 --> 00:29:26.440 importance. This wasn't just soft public relations. 00:29:26.660 --> 00:29:28.920 It was an acknowledgment that animal welfare 00:29:28.920 --> 00:29:31.619 is a critical component of their regulatory compliance 00:29:31.619 --> 00:29:34.920 and their scientific credibility. How so? Any 00:29:34.920 --> 00:29:37.559 failure in care risks the integrity of the research 00:29:37.559 --> 00:29:41.039 itself. And any public scandal risks their crucial 00:29:41.039 --> 00:29:43.240 institutional contracts, like the one with the 00:29:43.240 --> 00:29:46.809 NCI. Therefore... ensuring humane care is an 00:29:46.809 --> 00:29:49.410 operational necessity as much as it is an ethical 00:29:49.410 --> 00:29:51.569 mandate. What's remarkable is the simultaneous 00:29:51.569 --> 00:29:53.869 acknowledgement of their business prowess and 00:29:53.869 --> 00:29:56.509 this ethical requirement. In that same year, 00:29:56.549 --> 00:29:59.130 2002, the company was also named Company of the 00:29:59.130 --> 00:30:02.250 Year by the Boston Globe. And this simultaneity 00:30:02.250 --> 00:30:04.430 perfectly encapsulates the tightrope that Charles 00:30:04.430 --> 00:30:07.210 River Laboratories walks. The necessity of animal 00:30:07.210 --> 00:30:09.910 models for regulatory safety assessment, which 00:30:09.910 --> 00:30:11.910 saves human lives and brings variable medicine 00:30:11.910 --> 00:30:14.670 to market, is constant. But the ethical pushback 00:30:14.670 --> 00:30:17.289 is also constant. It forces the company to invest 00:30:17.289 --> 00:30:20.509 heavily in transparency, internal accountability, 00:30:20.710 --> 00:30:23.789 and finding alternatives, even as current regulations 00:30:23.789 --> 00:30:27.529 continue to require in vivo data. Navigating 00:30:27.529 --> 00:30:30.230 that inherent tension between scientific requirement 00:30:30.230 --> 00:30:33.029 and humane standards is central to their continued 00:30:33.029 --> 00:30:35.769 operation and profitability. It's a structural 00:30:35.769 --> 00:30:38.470 tension that really defines the entire CRO industry. 00:30:38.910 --> 00:30:41.289 So to bring this comprehensive deep drive to 00:30:41.289 --> 00:30:43.910 a close, let's synthesize the journey. We started 00:30:43.910 --> 00:30:46.829 with Henry Foster buying 1 ,000 rat cages in 00:30:46.829 --> 00:30:50.549 Boston in 1947, filling an unsexy but critical 00:30:50.549 --> 00:30:53.490 need for standardized research models. Today, 00:30:53.750 --> 00:30:56.250 Charles River Laboratories is a $4 billion global 00:30:56.250 --> 00:30:59.309 leader with over 20 ,000 employees. And their 00:30:59.309 --> 00:31:02.009 key function, even as their sophistication exploded, 00:31:02.329 --> 00:31:05.710 remains standardized rigor. They act as the necessary 00:31:05.710 --> 00:31:07.890 institutional bridge between basic scientific 00:31:07.890 --> 00:31:11.150 discovery and official regulatory approval. They 00:31:11.150 --> 00:31:13.410 moved from providing standard rodents, to genetically 00:31:13.410 --> 00:31:15.710 engineering sophisticated models, to managing 00:31:15.710 --> 00:31:18.730 full preclinical toxicology studies. And now... 00:31:19.019 --> 00:31:21.500 They are vertically integrated, manufacturing 00:31:21.500 --> 00:31:24.019 the complex viral vectors required for the most 00:31:24.019 --> 00:31:26.619 advanced gene therapies on Earth. They became 00:31:26.619 --> 00:31:29.440 indispensable through strategic financial integration, 00:31:29.819 --> 00:31:32.700 purchasing key toxicology leaders like Will Research 00:31:32.700 --> 00:31:35.319 and MPI Research to consolidate market share, 00:31:35.480 --> 00:31:38.619 and making that bold, multi -billion dollar pivot 00:31:38.619 --> 00:31:41.380 into specialized manufacturing via Cognate and 00:31:41.380 --> 00:31:44.119 Vagine. And concluding with the, so what for 00:31:44.119 --> 00:31:46.930 you, the listener. Charles River Laboratories 00:31:46.930 --> 00:31:49.730 is a definitive, powerful example of how specialized 00:31:49.730 --> 00:31:52.569 contract services have become utterly central 00:31:52.569 --> 00:31:55.549 to global pharmaceutical innovation. They enforce 00:31:55.549 --> 00:31:57.589 standardization, they drive efficiency, and they 00:31:57.589 --> 00:31:59.990 accelerate drug development timelines. However, 00:32:00.670 --> 00:32:04.210 this vast centralization of expertise also centralizes 00:32:04.210 --> 00:32:06.430 the complex ethical concerns inherent in the 00:32:06.430 --> 00:32:08.690 development process. And that demands constant 00:32:08.690 --> 00:32:10.930 vigilance and a proactive response to public 00:32:10.930 --> 00:32:12.890 scrutiny regarding the use of critical research 00:32:12.890 --> 00:32:16.440 models. all the way to horseshoe crabs. This 00:32:16.440 --> 00:32:18.640 incredible journey of expansion, integration, 00:32:19.039 --> 00:32:21.960 and capitalization, where the company goes from 00:32:21.960 --> 00:32:24.119 supplying the tool to manufacturing the final 00:32:24.119 --> 00:32:27.400 component, raises one final provocative thought 00:32:27.400 --> 00:32:30.119 for you to consider. Given their aggressive acquisition 00:32:30.119 --> 00:32:32.380 strategy, particularly in these cutting edge 00:32:32.380 --> 00:32:34.259 areas like contract development and manufacturing 00:32:34.259 --> 00:32:38.259 organizations, the CDMOs for gene therapy, how 00:32:38.259 --> 00:32:41.099 much further can companies like CRL integrate 00:32:41.099 --> 00:32:44.500 themselves into the drug creation ecosystem before 00:32:44.500 --> 00:32:47.220 they fundamentally stop being merely the pharmaceutical 00:32:47.220 --> 00:32:50.000 industry's partner and effectively become the 00:32:50.000 --> 00:32:52.619 pharmaceutical industry itself? What are the 00:32:52.619 --> 00:32:55.660 vast economic, scientific, and ethical implications 00:32:55.660 --> 00:32:58.160 of such concentrated, centralized expertise? 00:33:00.360 --> 00:33:03.039 It's a fascinating and a necessary question for 00:33:03.039 --> 00:33:05.319 a company whose foundations were built on just 00:33:05.319 --> 00:33:08.299 1 ,000 cages and a commitment to standardization. 00:33:08.740 --> 00:33:11.279 Thank you for joining us on this deep dive into 00:33:11.279 --> 00:33:13.799 Charles River Laboratories International, Inc. 00:33:13.920 --> 00:33:15.200 We hope you feel thoroughly informed.